Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/15207
Título
Telomerase as a Therapeutic Target in Cardiovascular Disease.
Autor(es)
Fecha de publicación
2021
Cita
Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1047-1061.
Idioma
Inglés
Tipo de documento
journal article
Resumen
Shortened telomeres have been linked to numerous chronic diseases, most importantly coronary artery disease, but the underlying mechanisms remain ill defined. Loss-of-function mutations and deletions in telomerase both accelerate telomere shortening but do not necessarily lead to a clinical phenotype associated with atherosclerosis, questioning the causal role of telomere length in cardiac pathology. The differential extranuclear functions of the 2 main components of telomerase, telomerase reverse transcriptase and telomerase RNA component, offer important clues about the complex relationship between telomere length and cardiovascular pathology. In this review, we critically discuss relevant preclinical models, genetic disorders, and clinical studies to elucidate the impact of telomerase in cardiovascular disease and its potential role as a therapeutic target. We suggest that the antioxidative function of mitochondrial telomerase reverse transcriptase might be atheroprotective, making it a potential target for clinical trials. Graphic Abstract: A graphic abstract is available for this article.
MESH
Animals | Biomarkers | Cardiovascular Diseases | Clinical Trials as Topic | Drugs, Chinese Herbal | Exercise | Genome-Wide Association Study | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Leukocytes | Mice | Models, Cardiovascular | Mutation | RNA | Telomerase | Telomere Homeostasis | Telomere Shortening
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Arterioscler Thromb Vasc Biol ...
- Tamaño:
- 1.584Mb
- Formato:
- Descripción:
- Artículo